Medicare Compliance & Reimbursement - 2005 Issue 19
DRUG ADMINISTRATION: Doctors Shouldn't Have To Promise Exact Date Of Drug Administration Under CAP
Subscribe or sign in to view the full article.
Article Overview
This article reviews stakeholder reactions to CMS's Competitive Acquisition Program (CAP) for Part B drugs and summarizes concerns raised by physician and pharmacy organizations. It covers the program's billing and administration timing, vendor and inventory logistics, regional contracting, emergency delivery expectations, and possible phase-in approaches. The piece is relevant for physicians, oncology and urology practices, managed care pharmacy professionals, and coding or reimbursement staff tracking Medicare drug acquisition policy.
Why This Topic Matters
Changes to drug acquisition and billing policy can affect practice workflow, documentation, vendor relationships, and Medicare reimbursement operations. Readers following Part B drug administration and CAP policy will want to understand the areas of concern raised by specialty groups before implementation.
Article Sections
-
Associations object to changes in the drug billing window
Summarizes comments from physician associations on the proposed timeframe for submitting claims related to drug administration and the broader administrative burden of the program.
-
Vendor participation, inventory, and record-keeping concerns
Covers concerns about supplier restrictions, handling unused drug inventory, and the administrative responsibilities expected of physicians and vendors.
-
Regional contracting and emergency supply issues
Describes comments about how CMS would select contractors by region and the need for timely drug delivery in urgent situations.
-
Calls for a broader or differently phased rollout
Summarizes recommendations from a specialty association regarding whether the program should launch broadly at once or be introduced in phases.
What You Will Learn
- How physician and specialty associations are responding to CMS's Competitive Acquisition Program for Part B drugs.
- Which operational concerns organizations raised about drug administration timing and documentation.
- What issues were identified regarding vendor selection, regional coverage, and emergency access.
- How specialty groups suggested the program be implemented or phased in.
Who Should Read This
- Physicians
- Oncology practices
- Urology practices
- Medical coders and billing staff
- Practice managers
- Managed care pharmacy professionals
- Reimbursement and compliance staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com